The pharmacodynamic activities of two beta adrenergic antagonists, propranolol and practolol, were compared in eight hypertensive patients. The activity of each antagonist was established in relation to its blood concentration at maximal and submaximal adrenergic blockade defined by inhibition of exercise tachycardia. Maximal inhibition of exercise tachycardia was comparable with both drugs and averaged 74±7% of the control value during drug treatment. This inhibition was achieved with a blood concentration of 2.5±0.4 µg/ml practolol and 0.10±0.08 µg/ml propranolol. The antagonist activities of these drugs against adrenergic stimulation with isoproterenol infusion indicated a much greater relative potency of propranolol against this stimulus, and in vivo estimates of PA 2 values differed by more than 600-fold. Relative antagonist activity of practolol during isoproterenol stimulation was equivalent both at cardiac (inotropic and chronotropic) and at vascular adrenergic receptors, whereas greater antagonist activity of propranolol was observed at vascular receptors than at cardiac receptors. Thus, the activity of practolol was not limited to cardiac receptors as previously suggested. Practolol did not reduce cardiac output at any dose level and the effect on resting blood pressure was small. Both practolol and propranolol had much greater hypotensive activity during exercise. These studies have defined the differing pharmacodynamic activities on the cardiovascular system of two effective beta adrenergic receptor antagonists and have established the blood levels of these […] Research Article
A B S T R A C T The pharmacodynamic activities of two beta adrenergic antagonists, propranolol and practolol, were compared in eight hypertensive patients. The activity of each antagonist was established in relation to its blood concentration at maximal and submaximal adrenergic blockade defined by inhibition of exercise tachycardia. Maximal inhibition of exercise tachycardia was comparable with both drugs and averaged 74±7% of the control value during drug treatment. This inhibition was achieved with a blood concentration of 2.5±0.4 Mg/ml practolol and 0.10±0.08 /ig/ml propranolol. The antagonist activities of these drugs against adrenergic stimulation with isoproterenol infusion indicated a much greater relative potency of propranolol against this stimulus, and in vivo estimates of PA2 values differed by more than 600-fold. Relative antagonist activity of practolol during isoproterenol stimulation was equivalent both at cardiac (inotropic and chronotropic) and at vascular adrenergic receptors, whereas greater antagonist activity of propranolol was observed at vascular receptors than at cardiac receptors. Thus, the activity of practolol was not limited to cardiac receptors as previously suggested. Practolol did not reduce cardiac output at any dose level and the effect on resting blood pressure was small. Both practolol and propranolol had much greater hypotensive activity during exercise. These studies have defined the differing pharmacodynamic activities on the cardiovascular system of two effective beta adrenergic receptor antagonists and have established the blood levels of these antagonists necessary to achieve effective adrenergic blockade.
INTRODUCTION
As the therapeutic indications for pharmacologic blockade of beta adrenergic receptors are broadened, it becomes increasingly important to define the specific pharmacodynamic activity of beta adrenergic antagonists in man. This is especially the case in the hypertensive patient where beta blockade with propranolol has been shown to effectively lower blood pressure (1, 2) . Such a response could be mediated by the adrenergic blpcking activity of this drug or by its nonspecific cardiodepressant activity (3) which may be present when large amounts of the drug are administered (1) .
Although the extent of pharmacologic blockade of beta adrenergic receptors always should be defined in patients receiving propranolol, this is often difficult to establish in the usual clinical study. Estimation of blockade involves an alteration of the heart rate response to intravenous isoproterenol or to exercise (4, 5) , both of which are techniques too difficult for ready clinical applicability. However, if the extent of pharmacologic blockade were established in a group of patients and compared with dose, or better still to blood levels of the drug, one could then extend these findings to other patients similarly treated. The comparison to blood levels is particularly appropriate with propranolol where almost 10-fold differences in blood levels can be demonstrated among patients after a standard oral dose of the drug (6) .
We have examined these questions in hypertensive patients where the pharmacodynamic activity of beta blockade was compared with the blood level of drug, and have contrasted our findings with propranolol to those obtained in the same patients with a new beta adrenergic antagonist, practolol. The latter drug differs from propranolol in that it has been reported to have a greater antagonist action on beta I as opposed to beta II adrenergic receptors (7) . Therefore, we wished to compare further the relative activity of these two
The Journal of Clinical Investigation Volume 52 April 1973 747 antagonists on both cardiac (beta I) and peripheral vascular (beta II) adrenergic receptors. The potencies of the two drugs also were evaluated in terms of their activities against two types of adrenergic stimulation, isoproterenol infusion and the adrenergic activation of muscular exercise.
METHODS
Eight patients with essential hypertension were admitted to the Clinical Research Center of the University of Colorado Medical Center where they were hospitalized during the 3 wk required for these studies. They ranged in age from 23 to 49 yr, two were female, and three were Negroes. Fully informed and written consent was obtained from these patients. During this time the patients received no other drugs and were maintained on a constant dietary intake with a sodium content which varied between 60 and 120 meq/day among the individual patients. The patients were treated sequentially with both beta antagonists in increasing doses over 7 days. Practolol was given first in incremental doses of 25, 50, 100, 200, 400, and 600 mg orally at 6-h intervals. This was followed by at least a 5 day recovery period during which time control cardiovascular responses were re-established. Thereafter, propranolol was administered in incremental doses of 10, 20, 40, 60, 80, and 120 mg orally at 6-h intervals. Increases were terminated when maximum blockade was achieved or the development of bradycardia prevented further. increases. Each dose level was given for 24 h before study. After stopping practolol blood samples, timed urine collections were made for 5-7 days to insure that all of the administered drug had been cleared from the body before the second study with propranolol.
Patients were studied daily 2 h after their last oral dose of beta antagonist and 1.5 h after their meal. At least three control measurements were made before giving antagonists in order to insure a consistent heart rate at rest and exercise during the last two measurements. Recovery measurements were made after practolol, and heart rates at rest and exercise were equivalent to control values. The Isoproterenol administration was increased until an increment in heart rate of 20-30 min' had been achieved. A minimal effective dose was considered as that amount of isoproterenol which produced the initial responses in heart rate (A HR = 20), in the pre-ejection period (PEP) of the systolic time interval (A PEP =25%), or in forearm vascular resistance (A FVR = 25%), and which could be compared with the isoproterenol responses observed during administration of antagonist. In one patient only a 10 minincrease occurred before the development of a transient nodal arrhythmia precluded further infusion. Cardiac output was measured in seven patients during the control period and during practolol administration.
Heart rates were obtained using precordial electrodes and polygraphic recordings of the electrocardiograms which were also monitored continually on an oscilloscope. Blood pressures were obtained by a sphygmomanometric method using an electronic technique of detecting Korotkoff sounds (model 1950, Avionics, Inc., South Bend, Ind.) and recording these with the electrocardiogram. Systolic time intervals were obtained from the simultaneously recorded electrocardiogram, phonocardiogram, and the carotid pulse; they were calculated by the method of Weissler and associates and expressed as percent of normal predicted values (8) . The pre-ejection period was used as the most sensitive index of contractility change. Forearm blood flow was measured using a water plethysmograph with the venous occlusion method (9) . Cardiac output was measured using the indicator dilution technique (10) with a right atrial injection of 2 ml of cardiogreen dye and sampling from an indwelling needle in the brachial artery.-Blood pressure was recorded with a Clark strain gage (no. 3047) and peripheral vascular resistance calculated from cardiac output and mean blood pressure. Propranolol was measured fluorimetrically after extraction from plasma (6) and practolol was measured after extraction from plasma and urine by a fluorimetric method recently reported from this laboratory (11) . Statistical analysis of the data was performed using the Wilcoxon sign rank test (12) .
RESULTS
Beta receptor blockade induced by either practolol or propranolol effected a significant reduction of heart rate ( Table I) . These responses will be examined first at the greatest pharmacologic effect which was achieved, as described in greater detail below. With practolol, a reduction of heart rate was observed only during tilt and exercise, whereas heart rate was unchanged at rest in the supine position. On the other hand, with propranolol, heart rate was reduced significantly at rest as well as during tilt and exercise. The extent of cardiac deceleration was comparable with these two adrenergic antagonists during tilt and exercise and, in the latter condition, the blocked heart rate at "maximum" exercise averaged 74% of the average control value during both practolol and propranolol (P < 0.001). This level of exercise was not equivalent to the estimated physiologic maximum of the patients since none of these individuals were conditioned. At minimum exercise (1.5 mph), the inhibition of the tachycardia response was observed to be somewhat smaller with the average blocked heart rate representing 82 and 78% of the average control value with practolol 'and pro- * Mean values differ significantly from control (P < 0.05). 1 Mean values differ significantly from control (P < 0.01). C, control; Pc, practolol; Pr, propranolol; Maximum, maximum level that the patient could be encouraged to achieve. C2 for P. M. was not obtained and value is taken from C1.
pranolol, respectively (P < 0.05, with each drug). A comparison of these exercise responses was made with those of two normal subjects in whom exercise to the true physiologic maximum was achieved. These studies indicated that the heart rate was comparably inhibited, as a fraction of the control value, at all exercise levels beyond that necessary to achieve a tachycardia of 125 min1 (Fig. 1) . Furthermore, the percentage blockade of control tachycardia at all rates above 125 min' was comparable at a given dose level and it became greater as increasing doses of the antagonist propranolol were administered. There was no apparent overriding of the blockade by increasing adrenergic stimuli when maximum exercise was accomplished with control heart rate of 172 min'; this was true even at a threshold dose of propranolol which had minimal pharmacologic effect (10 mg). A comparison of the relative antagonist potency was made with practolol and propranolol during increasing dosages of each drug. The heart rate, expressed as a fraction of the control rate, decreased during "maximum"I exercise as the level of antagonist in plasma increased during incremental dosing with these drugs (Fig. 2) . The maximal blockade which was achieved in this study was equivalent with practolol and propranolol and approximated 25% of the control exercise heart rate. Although a plateau of the inhibitory response to propranolol was not seen as with practolol, from previous observations it appears that this is indeed a maximal or plateau level (5, 13) . This maximal pharmacologic effect of the adrenergic antagonists was achieved with blood levels of practolol which averaged 2.5+0. 4 ,Ag/ml and of propranolol which averaged 0.10 +0.08 ng/ml. Thus, the potency of propranolol exceeds that of practolol by a factor of 25, whereas the maximal effect of the two antagonists is similar. In contrast to these blood levels, the differences between the daily doses of practolol and propranolol necessary to achieve the maximal blockade differed by only a factor of 5, 1050 mg/day for practolol and 200 mg/day for propranolol (Table I) . Control Heart Rate (min-) The antagonist activity of practolol in the range of doses used in these s assessed in relation to the pharmaco agonist, isoproterenol (Table II) . T responses of heart rate, the inotropic change in pre-ejection period, and th sponses of forearm vascular resistance by these antagonists (Fig. 3) . The r pharmacologic dose of isoproterenol change in the measured variable whic pared in control, propranolol, and p averaged 0.015, 0.012, and 0.004 itg/ spectively at the chronotropic, inotropi( vascular receptors (Table II) . The dose response was shifted consistently to the right during the administra-PRACTOLOL tion of both of these competitive antagonists. However, the relative potency of propranolol appeared to differ from practolol in its capacity to antagonize isoproterenol at the three adrenergic receptors. Propranolol was much more effective in antagonizing the peripheral responses to isoproterenol than those of the cardiac receptors. These responses required 21.9 (chronotropic), > 25.0 (inotropic), and > 84.8 (vascular) times the control isoproterenol dose at these same receptors during propranolol. This differential activity was seen even I 6 8 lo when adrenergic blockade was minimal (E. P., T. S., d error (of both In order to compare the relative potency of practolol and propranolol as antagonists to the agonist activity of isoproterenol the shift in threshold dose of isoproand propranolol, terenol was related to the plasma concentration of tudies, was also antagonist in these patients (Fig. 4) . The logarithm of logic adrenergic the minimal effective dose displacement for the chronohe chronotropic tropic response was plotted against the logarithm of responses of the the molar concentration of antagonist (14) . It is poste peripheral re-sible that the chronotropic response during isoproninmall effectved terenol is influenced by vagal withdrawal as well as (the minimal adrenergic stimulation from the infused agonist. Howh could be com-ever, despite our finding of the greater sensitivity of tractolol studies) vascular receptors to isoproterenol there was little alterkg per min, re-ation of blood pressure at the minimal dose of isoproc, and peripheral terenol which effectively increased heart rate (AHR= Precise evaluation of the effect of these antagonists on blood pressure could not be made because the design of the study was not directed toward this goal. However, it is apparent that the resting blood pressure, during the lowest dose of either antagonist which produced the maximal inhibition of exercise tachycardia, was also little changed by practolol (Table III) . The decline in blood pressure during practolol was small and only significant in comparison to the pretreatment control. However, there was no significant reduction in pressure in comparison to the post-treatment control, when the drug had been cleared from the body and its pharmacologic effect on heart rate was absent (Table  I) . During propranolol only a small hypotensive response was present at rest. However, in contrast to the minimal effects on blood pressure in the resting state both drugs strikingly reduced systolic blood pressure during "maximal" exercise. When the hemodynamic response to practolol was examined at doses equal to or exceeding that necessary for maximal pharmacologic activity, little change was observed (Table IV) . Thus, cardiac output was unchanged and there was only a small reduction in blood pressure. Vascular resistance and right atrial pressure were unaffected.
DISCUSSION
These studies have defined the pharmacologic effect of two adrenergic antagonists in terms of their blood concentrations using inhibition of the adrenergic component of exercise tachycardia as one criterion of this effect. Maximal inhibition of exercise tachycardia ob- served in this study was achieved with a blood level of propranolol of 0.10 ihg/ml whereas 2.5 tag/ml of practolol in the blood was required for the same pharmacologic effect. The value of 0.10 /Ag/ml of propranolol is slightly higher than 0.04 /g/ml reported by Coltart and Shand to be necessary to achieve maximal adrenergic blockade of exercise tachycardia (13 FIGURE 4 A plot of antagonist activity of propranolol (0) and practolol (a) against the concentration of drug. Antagonist activity is expressed as the logarithm of the ratio of minimum effective doses during antagonist (EDA) and control (EDc) minus one. Antagonist concentration is expressed as its negative logarithm. The correlation coefficients expressed are each significant (P < 0.01).
pranolol method (15) . Since this is apparently only formed after an initial oral dose and not after multiple doses (16) , it may be that our studies involving multiple dosing may define more accurately the blood concentration-pharmacodynamic relationship with chronic therapy. In contrast to these considerations of metabolites with propranolol, no such difficulty is present with practolol since this drug is not metabolically transformed.'
Although our patients were not exercised to their true physiological maximum, heart rate at their highest exercise level was maximally inhibited to 74% of the control value by both propranolol and practolol. Practolol clearly had achieved its greatest pharmacologic effect as a plateau in the response to this drug was observed. Despite the lack of response plateau to propranolol (Fig. 2) , we inferred that its maximum effect was achieved since this response was equal to that of practolol and since this was the relative degree of block1Bodem, G., and C. A. Chidsey. Unpublished observations. ade which Coltart and Shand achieved in studies where a response plateau was demonstrated for propranolol (13) . The level of blockade of exercise tachycardia in our studies was greater than that achieved by earlier experiments using maximum exercise in normal subjects (5) . This then appears to be the maximal inhibition of exercise tachycardia which can be achieved with adrenergic blockade. Furthermore, this adrenergic component of exercise tachycardia appeared to be a relatively constant fraction of the control heart rate at levels of exercise which generated unblocked heart rates from 125 min' to the true physiologic maximum exercise level as shown in normal control subjects (Fig.  1) . Therefore, the responses which were observed in the patients can be considered to be comparable within the group despite the fact that their "maximum" exercise levels differed, producing control heart rates which varied between 133 and 163 min'.
A comparison of the pharmacologic activity of practolol and propranolol suggested a substantial difference (7, 19) . Using the classification of beta receptors recently proposed (20) , practolol had antagonist activity at the type II adrenergic vascular receptors which was equivalent to its activity at the type I adrenergic cardiac receptors. In contrast propranolol had more activity at the type II adrenergic receptor than at the type I receptor. Thus, our evidence does not support the concept that practolol is exclusively a type I adrenergic receptor antagonist and suggests greater type II antagonism for propranolol than had been previously recognized.
We have found no reduction in cardiac output at doses of practolol which produced blood levels of 2.6-13.6 /Ag/ml. Thus, no cardiodepression was observed even at doses in excess of those necessary to achieve Pharmacodynamics of Adrenergic Antagonism 753 a full pharmacologic effect. These data are consistent with a recent report of Leon and associates (21) . The hypotensive activity of practolol and propranolol was most apparent during exercise when significant reduction of systolic blood pressure was observed with both antagonists. At rest neither drug reduced blood pressure greatly. These studies were not designed critically to evaluate the hypotensive activity of the antagonists, but the minimal blood pressure changes which we have observed are consistant with previously published observations (21) . There was an apparent decline in blood pressure during practolol, but this may have been due to an initial adaptation to the study as seen in the fall in blood pressure between the first and second control periods (Table IV) . This was not the consequence of residual practolol or its pharmacologic effect because the drug had been cleared from the body and heart rates had returned to control values (Table I) . In contrast to practolol, propranolol did have a small but demonstrable hypotensive effect and this difference may relate to the cardiac output reduction seen with propranolol (2). Propranolol appears to have greater antihypertensive activity when administered chronically (1) . Recent observations that propranolol inhibits renin release (22) may suggest a mechanism whereby its lowers blood pressure in the hypertensive patient. Another use of propranolol in hypertension has been suggested in its combination with vasodilators (10) and practolol might be of value with such combined therapy because of its lesser activity in antagonizing the beta receptors in the arterial resistance vessels.
